GSK
GSK
818 hedge funds and large institutions have $11.1B invested in GSK in 2020 Q4 according to their latest regulatory filings, with 112 funds opening new positions, 245 increasing their positions, 345 reducing their positions, and 107 closing their positions.
7% more call options, than puts
Call options by funds: $105M | Put options by funds: $98.5M
5% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 107
0.06% more ownership
Funds ownership: 4.75% → 4.81% (+0.06%)
0% less capital invested
Capital invested by funds: $11.2B → $11.1B (-$49.9M)
1% less funds holding
Funds holding: 826 → 818 (-8)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
29% less repeat investments, than reductions
Existing positions increased: 245 | Existing positions reduced: 345
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$659M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$121M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$112M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$109M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$76.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$149M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$103M |
| 3 |
Rockefeller Capital Management
New York
|
-$98.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$84.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$83.3M |
GSK Hedge Fund Activity: Q4 2020 in Review
818 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2020, worth a combined $11.1B — down 0.45% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new GSK positions and 107 closed out — a net gain of 5 holders — while 245 added to existing stakes and 345 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $659M. The largest seller was Renaissance Technologies, cutting an estimated $149M.
- 818 institutional investors held GSK (GSK) as of Q4 2020, down from 826 in Q3 2020.
- Funds reported $11.1B of GSK stock for Q4 2020, down 0.45% quarter-over-quarter.
- 112 funds opened new GSK positions in Q4 2020 and 107 closed out, a net change of +5 holders.
- The largest GSK buyer in Q4 2020 was Dodge & Cox, an estimated $659M added.
- The largest GSK seller in Q4 2020 was Renaissance Technologies, an estimated $149M sold.
Based on aggregated 13F filings for Q4 2020.